Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Cue Biopharma (CUE) over the last 5 years, with Q3 2025 value amounting to $100.9 million.

  • Cue Biopharma's Shares Outstanding (Diluted Average) rose 9689.62% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.9 million, marking a year-over-year increase of 9689.62%. This contributed to the annual value of $56.3 million for FY2024, which is 2310.92% up from last year.
  • As of Q3 2025, Cue Biopharma's Shares Outstanding (Diluted Average) stood at $100.9 million, which was up 9689.62% from $95.5 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Shares Outstanding (Diluted Average) ranged from a high of $100.9 million in Q3 2025 and a low of $31.3 million during Q4 2021
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $45.8 million (2023), whereas its average is $50.6 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 1050.75% in 2024, then soared by 9689.62% in 2025.
  • Over the past 5 years, Cue Biopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $31.3 million in 2021, then grew by 13.95% to $35.6 million in 2022, then rose by 28.35% to $45.8 million in 2023, then grew by 23.11% to $56.3 million in 2024, then skyrocketed by 79.07% to $100.9 million in 2025.
  • Its last three reported values are $100.9 million in Q3 2025, $95.5 million for Q2 2025, and $74.3 million during Q1 2025.